Distinguished Experts in Disease Diagnosis and Diagnostics Technology Bring World Class Scientific Acumen and Insight to Help Guide the New Merged Company’s Expansion and Growth
Other Recent Pre-Merger Developments Include EPO Decision to Grant Patent Protection in Europe for Transgenomic’s Multiplexed ICE COLD-PCR and Completion of Reverse Stock Split
NEW HAVEN, Conn. and OMAHA, Neb., (June 16, 2017) — Precipio Diagnostics and Transgenomic, Inc. (OTCQB: TBIOD) today announced the formation of a new Scientific Advisory Board (SAB) in anticipation of their previously disclosed merger. The new SAB, which will become effective on the closing of the merger, is being established to provide scientific and technical guidance and expertise to the combined company’s management and board of directors in support of current and future business initiatives. SAB members include Dr. Jeffrey Sklar of the Yale University School of Medicine, Dr. Mike Makrigiorgos of Harvard Medical School and the Dana-Farber Cancer Institute, and Dr. Gil Mor of the Yale University School of Medicine.
SAB Chair Jeffrey Sklar, MD, PhD, is a Professor of Pathology and Laboratory Medicine and Director of the Molecular Diagnostics Research Program at the Yale School of Medicine. He is a pioneer in the field of molecular diagnostics and is responsible for many innovations and discoveries related to cancer diagnostics. Dr. Sklar has also served as a scientific advisor and director at a number of biotechnology companies. He received his MD and PhD degrees from Yale and completed a residency in pathology and a post-doctoral fellowship at Stanford University, where he also served as an Associate Professor. Previously, Dr. Sklar was a Professor of Pathology at Harvard Medical School.